A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study

作者：Meiting Chen, Lu Li, Qing Xia, Xiaobing Chen, Zijun Liao, Chang Wang, Bo Shen, Min Zhou, Qingyuan Zhang, Yanqiao Zhang, Liting Qian, Xianglin Yuan, Zhehai Wang, Cong Xue, Xin An, Bin Liu, Kangsheng Gu, Mei Hou, Xiaojia Wang, Wei Wang, Enxiao Li, Jin‐Cai Zhong, Jing Cheng, Yongqian Shu, Nong Yang, Huaqing Wang, Runxiang Yang, Tianshu Liu, Ting Deng, Fei Ma, Wangjun Liao, Wensheng Qiu, Yu Chen, Xi Chen, Mingzhi Zhang, Ruilian Xu, Xiaoling Li, Jifeng Feng, Yi Ba, Yanxia Shi · 发表于：Cancer · 年份：2024 · DOI：10.1002/cncr.35292 · 被引用次数：17 · 研究领域：Platelet Disorders and Treatments、Heparin-Induced Thrombocytopenia and Thrombosis、Neutropenia and Cancer Infections

Abstract Background Studies on various thrombopoietic agents for cancer treatment–induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens. Methods In this retrospective, cross‐sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL‐11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO‐RA). The outcomes, compliance, and safety of different treatments were analyzed. Results Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL‐11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL‐11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy‐induced thrombocytopenia (CIT) than rhIL‐11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 10 9 /L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show tha...